Fig. 7: PUFA supplementation alleviates FABP3-induced ER stress.
Effects of DHA on fluidity (a), ER stress signal (b), and morphology (c). FABP3 expression was induced with Cre recombinase-carrying adenovirus (Ad-Cre) infected into fully differentiated C2C12 myotubes harboring Cre-inducible FABP3 constructs. FABP3-overexpressing myotubes or palmitate (500 μM)-treated myotubes were treated with DHA (100 μM) or vehicle. a Membrane fluidity was measured by FRAP analysis. Note the t1/2 values in FRAP analyses. Black, control, n = 6; gray, DHA, n = 6; deep blue, palmitate, n = 5; light blue, palmitate+DHA, n = 9; red, FABP3, n = 5; light red, FABP3+DHA, n = 9 each myotube. b Immunoblot analysis (left) and quantification (right) of the indicated proteins and puromycin incorporation. Myotubes were incubated with puromycin (1 μM) for 30 min (n = 3 independent experiments). c the effect of DHA supplementation on FABP3-induced loss of atrophy recovery. FABP3-overexpressing or palmitate-treated myotubes were treated with dexamethasone (10 μM). Representative images (left) of MyHC (green) and DAPI (blue) staining in myotubes following DHA supplementation (100 μM) for 24 h (n = 3 independent experiments). Scale bar, 100 μm. Quantification (right) of myotubes diameter treated with dexamethasone. Data are presented as means ± S.E.M. Two-tailed unpaired Student’s t-test was used. Source data are provided as a Source Data file.
